Cases of true chemo-induced pseudocellulitis resembled infectious cellulitis; did not meet diagnostic criteria for known diagnoses<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, July 5, 2023 (HealthDay News) — Chemotherapy-induced adverse cutaneous drug reactions that mimic cellulitis, including those termed pseudocellulitis, do not meet criteria for other diagnoses, according to a review published online June 28 in JAMA Dermatology<\/em>.<\/p>\n Leah D. Kovacs, from the University of Washington School of Medicine in Seattle, and colleagues conducted a systematic review of case reports of patients with pseudocellulitis to characterize the various cellulitis-mimicking reactions caused by chemotherapeutic medications and understand how these reactions affect patient care. Data were obtained from 32 publications, representing 81 patients with pseudocellulitis.<\/p>\n The researchers found that most of the 81 cases were associated with gemcitabine use, while pemetrexed use was reported less often. Thirty-nine cases were considered true chemotherapy-induced pseudocellulitis. These did not meet diagnostic criteria for any known diagnoses and resembled pseudocellulitis and were therefore described solely as pseudocellulitis. Sixty-seven and 36 percent of this group (26 and 14 patients) had been administered antibiotics before the correct diagnosis and experienced interruptions to their oncologic treatment plans, respectively.<\/p>\n “There is a need for a universally accepted definition of pseudocellulitis,” the authors write. “A greater understanding of chemotherapy-induced pseudocellulitis would help to avoid oncologic interruptions and would promote antimicrobial stewardship.”<\/em><\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n